Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, McCoy A, Houston N, Lee JM, Lipkowitz S, Zimmer A, Pavelova M, Villanueva EN, Smith L, Blakely A, Casablanca Y, Highfill SL, Stroncek DF, Collins-Johnson N, Panch S, Procter J, Pham C, Korrapati S, Holland SM, Rosen LB, Nunes AT, Zoon KC, Cole CB, Annunziata CM. Green DS, et al. Among authors: pham c. Clin Cancer Res. 2023 Jan 17;29(2):349-363. doi: 10.1158/1078-0432.CCR-22-1893. Clin Cancer Res. 2023. PMID: 36099324 Free PMC article. Clinical Trial.
Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use.
Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, Zoon KC, Annunziata CM. Green DS, et al. Among authors: pham c. J Transl Med. 2019 Mar 14;17(1):82. doi: 10.1186/s12967-019-1822-6. J Transl Med. 2019. PMID: 30871636 Free PMC article.
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, McCoy A, Houston N, Lee JM, Lipkowitz S, Zimmer A, Pavelova M, Villanueva EN, Smith L, Blakely A, Casablanca Y, Highfill SL, Stroncek DF, Collins-Johnson N, Panch S, Procter J, Pham C, Korrapati S, Holland SM, Rosen LB, Nunes AT, Zoon KC, Cole CB, Annunziata CM. Green DS, et al. Among authors: pham c. Clin Cancer Res. 2023 Jan 17;29(2):501. doi: 10.1158/1078-0432.CCR-22-3833. Clin Cancer Res. 2023. PMID: 36647676 No abstract available.
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL, Le TA, Pham CP, Hoa Nguyen TT, Do AT, Nguyen TK, Nguyen MH, Thu Hoang TA, Hao Vuong DT, Tam Nguyen DN, Khiem Dang V, Nguyen TO, Trang Vo TH, Do HK, Vu HT, Nguyen TTH, Pham VT, Trinh LH, Dung Nguyen K, Nguyen HG, Truong CM, Chau Pham TM, Nguyen TBP. Pham VL, et al. Among authors: pham cp. Ther Adv Med Oncol. 2024 May 9;16:17588359241242972. doi: 10.1177/17588359241242972. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38736554 Free PMC article.
1,015 results